Related references
Note: Only part of the references are listed.Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities
David E. Reuss et al.
ACTA NEUROPATHOLOGICA (2015)
ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an integrated diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma
David E. Reuss et al.
ACTA NEUROPATHOLOGICA (2015)
Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma
Felix Sahm et al.
ACTA NEUROPATHOLOGICA (2014)
International Society of Neuropathology-Haarlem Consensus Guidelines for Nervous System Tumor Classification and Grading
David N. Louis et al.
BRAIN PATHOLOGY (2014)
Clinical Neuropathology practice news 2-2014: ATRX, a new candidate biomarker in gliomas
Christine Haberler et al.
CLINICAL NEUROPATHOLOGY (2014)
IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection
Jason Beiko et al.
NEURO-ONCOLOGY (2014)
ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis
Benedikt Wiestler et al.
ACTA NEUROPATHOLOGICA (2013)
Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Newly Diagnosed Anaplastic Oligodendroglioma: Long-Term Follow-Up of EORTC Brain Tumor Group Study 26951
Martin J. van den Bent et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Survival and Prognostic Factors of Anaplastic Gliomas
Miriam Nuno et al.
NEUROSURGERY (2013)
IDH1 Mutations in Diffusely Infiltrating Astrocytomas Grade Specificity, Association With Protein Expression, and Clinical Relevance
Balaram Thota et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2012)
Anaplastic Glioma
Nina A. Paleologos et al.
CURRENT TREATMENT OPTIONS IN NEUROLOGY (2012)
Molecular prognostic factors of anaplastic oligodendroglial tumors and its relationship: a single institutional review of 77 patients from China
Shouwei Li et al.
NEURO-ONCOLOGY (2012)
Molecular pathology in adult high-grade gliomas: from molecular diagnostics to target therapies
K. Masui et al.
NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY (2012)
Prognostic Implication of Histological Oligodendroglial Tumor Component: Clinicopathological Analysis of 111 Cases of Malignant Gliomas
Hiromi Kanno et al.
PLOS ONE (2012)
Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas
Yuchen Jiao et al.
ONCOTARGET (2012)
Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas
Christian Hartmann et al.
ACTA NEUROPATHOLOGICA (2010)
Molecular diagnostics of gliomas: state of the art
Markus J. Riemenschneider et al.
ACTA NEUROPATHOLOGICA (2010)
Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician's perspective
Martin J. van den Bent
ACTA NEUROPATHOLOGICA (2010)
The Pathobiology of Glioma Tumors
Candece L. Gladson et al.
ANNUAL REVIEW OF PATHOLOGY-MECHANISMS OF DISEASE (2010)
Characterization of R132H Mutation-specific IDH1 Antibody Binding in Brain Tumors
David Capper et al.
BRAIN PATHOLOGY (2010)
Molecular pathology in adult gliomas: diagnostic, prognostic, and predictive markers
Michael Jansen et al.
LANCET NEUROLOGY (2010)
MGMT promoter methylation in malignant gliomas: ready for personalized medicine?
Michael Weller et al.
NATURE REVIEWS NEUROLOGY (2010)
MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma
Andreana L. Rivera et al.
NEURO-ONCOLOGY (2010)
Monoclonal antibody specific for IDH1 R132H mutation
David Capper et al.
ACTA NEUROPATHOLOGICA (2009)
Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas
Christian Hartmann et al.
ACTA NEUROPATHOLOGICA (2009)
Molecular Neuropathology of Gliomas
Markus J. Riemenschneider et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2009)
MGMT Promoter Methylation Is Prognostic but Not Predictive for Outcome to Adjuvant PCV Chemotherapy in Anaplastic Oligodendroglial Tumors: A Report From EORTC Brain Tumor Group Study 26951
Martin J. van den Bent et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
NOA-04 Randomized Phase III Trial of Sequential Radiochemotherapy of Anaplastic Glioma With Procarbazine, Lomustine, and Vincristine or Temozolomide
Wolfgang Wick et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas
Koichi Ichimura et al.
NEURO-ONCOLOGY (2009)
Analysis of the IDH1 codon 132 mutation in brain tumors
Joerg Balss et al.
ACTA NEUROPATHOLOGICA (2008)
Anaplastic astrocytomas: biology and treatment
Marc C Chamberlain et al.
Expert Review of Neurotherapeutics (2008)
Anaplastic oligodendrogliomas with 1p19q codeletion have a proneural gene expression profile
Francois Ducray et al.
MOLECULAR CANCER (2008)
Intratumoral distribution of 1p loss in oligodendroglial tumors
Johan M. Kros et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2007)
Molecular genetic markers as predictors of response to chemotherapy on gliomas
Ahmed Idbaih et al.
CURRENT OPINION IN ONCOLOGY (2007)
The 2007 WHO classification of tumours of the central nervous system
David N. Louis et al.
ACTA NEUROPATHOLOGICA (2007)
Panel review of anaplastic oligodendroglioma from European Organization for Research and Treatment of Cancer Trial 26951: Assessment of consensus in diagnosis, influence of 1p/19q loss, and correlations with outcome
Johan M. Kros et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2007)
Prognostic stratification of patients with anaplastic gliomas according to genetic profile
Caroline Dehais et al.
CANCER (2006)
Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: A prospective GICNO study
Alba A. Brandes et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment
Mathilde C. M. Kouwenhoven et al.
EUROPEAN JOURNAL OF CANCER (2006)
Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402
Gregory Cairncross et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas
H Ohgaki et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2005)
MGMT gene silencing and benefit from temozolomide in glioblastoma
ME Hegi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Molecular pathogenesis of oligodendroglial tumors
JWM Jeuken et al.
JOURNAL OF NEURO-ONCOLOGY (2004)
Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project
ER Laws et al.
JOURNAL OF NEUROSURGERY (2003)
Glioma classification - A molecular reappraisal
DN Louis et al.
AMERICAN JOURNAL OF PATHOLOGY (2001)
Malignant glioma: genetics and biology of a grave matter
EA Maher et al.
GENES & DEVELOPMENT (2001)
Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas
GS Bauman et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2000)
Share Paper
